BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hoel IM, Jørstad MD, Marijani M, Ruhwald M, Mustafa T, Dyrhol-Riise AM. IP-10 dried blood spots assay monitoring treatment efficacy in extrapulmonary tuberculosis in a low-resource setting. Sci Rep 2019;9:3871. [PMID: 30846768 DOI: 10.1038/s41598-019-40458-0] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
Number Citing Articles
1 Chendi BH, Tveiten H, Snyders CI, Tonby K, Jenum S, Nielsen SD, Hove-Skovsgaard M, Walzl G, Chegou NN, Dyrhol-Riise AM. CCL1 and IL-2Ra differentiate Tuberculosis disease from latent infection Irrespective of HIV infection in low TB burden countries. J Infect 2021:S0163-4453(21)00379-0. [PMID: 34333033 DOI: 10.1016/j.jinf.2021.07.036] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
2 Mann TN, Warwick J, Chegou NN, Davis JH, Beltran CGG, Griffith-Richards S, Kidd M, du Toit J, Lamberts RP, Walzl G. Biomarkers to predict FDG PET/CT activity after the standard duration of treatment for spinal tuberculosis: An exploratory study. Tuberculosis (Edinb) 2021;129:102107. [PMID: 34261033 DOI: 10.1016/j.tube.2021.102107] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
3 Can S, Sahin A, Dalgic N, Aygün D. The Diagnostic Value of Blood and Urine IP-10 Test in Children Having Active Tuberculosis or Latent Tuberculosis Infection. Journal of Pediatric Infectious Diseases 2021;16:216-22. [DOI: 10.1055/s-0041-1731039] [Reference Citation Analysis]
4 Rambaran S, Naidoo K, Lewis L, Hassan-Moosa R, Govender D, Samsunder N, Scriba TJ, Padayatchi N, Sivro A. Effect of Inflammatory Cytokines/Chemokines on Pulmonary Tuberculosis Culture Conversion and Disease Severity in HIV-Infected and -Uninfected Individuals From South Africa. Front Immunol 2021;12:641065. [PMID: 33868272 DOI: 10.3389/fimmu.2021.641065] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
5 Ambreen A, Khaliq A, Naqvi SZH, Tahir A, Mustafa M, Chaudhary SU, Mirza S, Mustafa T. Host biomarkers for monitoring therapeutic response in extrapulmonary tuberculosis. Cytokine 2021;142:155499. [PMID: 33799008 DOI: 10.1016/j.cyto.2021.155499] [Reference Citation Analysis]
6 Chendi BH, Snyders CI, Tonby K, Jenum S, Kidd M, Walzl G, Chegou NN, Dyrhol-Riise AM. A Plasma 5-Marker Host Biosignature Identifies Tuberculosis in High and Low Endemic Countries. Front Immunol 2021;12:608846. [PMID: 33732236 DOI: 10.3389/fimmu.2021.608846] [Cited by in Crossref: 2] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
7 Suárez I, Rohr S, Stecher M, Lehmann C, Winter S, Jung N, Priesner V, Berger M, Wyen C, Augustin M, Malin JJ, Fischer J, Horn C, Neuhann F, Püsken M, Plum G, Fätkenheuer G, Rybniker J. Plasma interferon-γ-inducible protein 10 (IP-10) levels correlate with disease severity and paradoxical reactions in extrapulmonary tuberculosis. Infection 2021;49:437-45. [PMID: 33140838 DOI: 10.1007/s15010-020-01541-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Yong YK, Tan HY, Saeidi A, Wong WF, Vignesh R, Velu V, Eri R, Larsson M, Shankar EM. Immune Biomarkers for Diagnosis and Treatment Monitoring of Tuberculosis: Current Developments and Future Prospects. Front Microbiol 2019;10:2789. [PMID: 31921004 DOI: 10.3389/fmicb.2019.02789] [Cited by in Crossref: 21] [Cited by in F6Publishing: 31] [Article Influence: 7.0] [Reference Citation Analysis]